IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Zoser B. Salama Examiner:

Serial No.: To Be Assigned Art Unit:

Filed: Concurrently Atty. Dkt.: 7014-190

For: NOVEL CHELIDONINE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR PRODUCING PHARMACEUTICAL

THEREOF, AND USE THEREOF FOR PRODUCING PHARMACEUTICAL AGENTS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. § 1.56, 1.97 and 1.98, Applicant submits on form PTO/SB/08a submitted herewith a listing of publications that the Office may wish to consider in the examination of the subject application. All documents listed were cited in the International Search Report that is also being submitted herewith. These documents should be part of the National Stage file.

No fee is believed to be due. However, the Commissioner is authorized to charge deposit account no. 50-3135 as required for consideration of this submission.

Respectfully submitted.

By /Joyce v. Natzmer/ Joyce von Natzmer Reg. No. 48,120 Customer No. 46002 Hall, Vande Sande & Pequignot, LLP (301) 657-1282

May 5, 2006

Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor	Ze	oser B. Salama
Art Unit		
Examiner Name		
Attornov Docket Numb	nr	7014 100

				_							_
					U.S.	PATENTS			Remove		_
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1										
If you wisl	h to a	i dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of cited Decument		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add		Ξ
				FOREIG	GN PAT	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	or '	vhere Rel	or Relevant	١.
	1	WO 02/092085	wo			2002-11-21	Chae Soo-Wan et a	x.			
If you wisl	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		_
Examiner Initials*	Cite No	Include name of the ai (book, magazine, jour publisher, city and/or of	nal, seria	al, symp	osium,	catalog, etc), o					т

Application Number | Fing Date | First Named Inventor | Zoser B. Salama | Art Unit | Examiner Name | Examiner

1	Crynkiewicz, et al., "Synthesis and Biological Activity of O-acyl and O-alityl Chelidonine Derivatives," European Journal of Medicinal Chemistry Editions Scientifique Elsevier, Paris, France, Vol. 36, No. 11-12, pages 951-960, November 2001.	

If you wish to add additional non-patent literature document citation information please click the Add button Add

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 199) Art Unit

Application Number			
Filing Date			
First Named Inventor	Ze	oser B. Salama	
Art Unit			
Examiner Name			
Attorney Docket Number	or	7014-190	_

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate selection(s)	
---------------	----------	------------------	------------------------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 177(vi).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- Z None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

of the agriculture.								
Signature	/Joyce v. Natzmer/	Date (YYYY-MM-DD)	2006-05-05					
Name/Print	Joyce von Natzmer	Registration Number	48120					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradentary Cfinge. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DING SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral purpuses for which the information is used by the U.S. Patient and Trademan Colline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested region of the patient of the patient application of the patient application of the patient activities, which may result in farministion of proceedings or 4 anahoroment of the application of the patients of the pa

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be discbesed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 152(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published anglication, an application open to public inspections or in several resources.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.